Latest Industry Insights

There remains an active debate within the psychedelic community about the importance of psychedelic experiences to these drugs’ therapeutic effects. Delix Therapeutics is developing compounds, called psychoplastogens, that act similarly to psychedelic compounds at the molecular level but do not induce hallucinations. We spoke with the Delix team to find out more about their research's progress.

This article discusses the importance of data lineage and traceability for academic labs looking to maximize their publishing potential.

In this article, Technology Networks speaks with Mindset Pharma CEO James Lanthier about how patents work in the fast-changing psychedelics industry, what makes a patent effective and how newer compounds stack up against natural psychedelics.

In this interview, we speak to research scientist Tobias Whelan, who is conducting a first-ever mechanistic study of psilocybin in autistic adults to understand how the serotonin system may differ in autistic and non-autistic individuals.

In this interview, we speak to Alon Ben-Noon, CEO and co-founder of Neurosense Therapeutics to hear about the impact their drug development strategy is having on the ALS field.

This article explores the current state of brain-computer interface technology and some of the ethical considerations associated with its use.

Frank Pun discusses how scientists from Insilico Medicine identified numerous unreported potential therapeutic targets of amyotrophic lateral sclerosis using the company’s proprietary AI-enabled biological target discovery platform.

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.

To learn more about Kai – an AI-powered personal guide and companion – and the potential benefits of using AI as a wellness tool for mental health, Technology Networks spoke to Alex Frenkel.

Delix Therapeutics is developing non-hallucinogenic psychedelics for use as at-home medications for mental health conditions. To find out more, we spoke to the CEO, Mark Rus.